176 related articles for article (PubMed ID: 12369129)
1. [Calcitriol dose optimization in the treatment of secondary hyperparathyroidism during dialysis. Results at 6 months].
Rodríguez García M; Fernández Martín JL; Ruiz de Castañeda J; Hervás Sánchez J; Cannata Andía JB;
Nefrologia; 2002; 22(4):370-6. PubMed ID: 12369129
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
[TBL] [Abstract][Full Text] [Related]
4. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
Sprague SM; Llach F; Amdahl M; Taccetta C; Batlle D
Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365
[TBL] [Abstract][Full Text] [Related]
5. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
[TBL] [Abstract][Full Text] [Related]
6. Advantages of adjusting the initial dose of intravenous calcitriol according to PTH levels.
Rodríguez-García M; Fernández-Martín JL; de Castañeda JR; Hervás-Sánchez J; Cannata-Andía JB;
Kidney Int Suppl; 2003 Jun; (85):S79-82. PubMed ID: 12753272
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
Malberti F; Corradi B; Cosci P; Calliada F; Marcelli D; Imbasciati E
Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
[TBL] [Abstract][Full Text] [Related]
8. Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism.
Costa AF; dos Reis LM; Ribeiro MC; Moysés RM; Jorgetti V
Nephrol Dial Transplant; 2003 Apr; 18(4):743-9. PubMed ID: 12637644
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient.
Rodriguez M; Caravaca F; Fernandez E; Borrego MJ; Lorenzo V; Cubero J; Martin-Malo A; Betriu A; Jimenez A; Torres A; Felsenfeld AJ
Kidney Int; 1999 Jul; 56(1):306-17. PubMed ID: 10411707
[TBL] [Abstract][Full Text] [Related]
10. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
11. Effect of CAPD and hemodialysis on parathyroid function.
Malberti F; Corradi B; Imbasciati E
Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
[TBL] [Abstract][Full Text] [Related]
12. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
[TBL] [Abstract][Full Text] [Related]
14. [Low dosage intravenous calcitriol bolus therapy in chronic hemodialysis patients].
Neyer U; Wöss E; Drexel H
Acta Med Austriaca; 1994; 21(5):129-32. PubMed ID: 7709710
[TBL] [Abstract][Full Text] [Related]
15. 1,25-(OH)2-16ene-23yne-D3 reduces secondary hyperparathyroidism in uremic rats with little calcemic effect.
Lippuner K; Perrelet R; Casez JP; Popp A; Uskokovic MR; Jaeger P
Horm Res; 2004; 61(1):7-16. PubMed ID: 14646396
[TBL] [Abstract][Full Text] [Related]
16. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism.
Malberti F; Surian M; Cosci P
Nephrol Dial Transplant; 1992; 7(8):822-8. PubMed ID: 1325615
[TBL] [Abstract][Full Text] [Related]
17. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
[TBL] [Abstract][Full Text] [Related]
18. Different effects of calcitriol and parathyroidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism.
Malberti F; Corradi B; Cosci P; Colecchia M; Leopardi O; Grossi L; Oldini C; Imbasciati E
Nephrol Dial Transplant; 1996 Jan; 11(1):81-7. PubMed ID: 8649657
[TBL] [Abstract][Full Text] [Related]
19. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol.
Shigematsu T; Kawaguchi Y; Unemura S; Yamamoto H; Momose M; Yokoyama K; Wakabayashi Y; Ikeda M; Hasegawa T; Sakai O
Intern Med; 1993 Sep; 32(9):695-701. PubMed ID: 8142673
[TBL] [Abstract][Full Text] [Related]
20. 1.25(OH)2 cholecalciferol pulse therapy and the effects of different dialysis membranes on serum PTH levels of haemodialysis patients.
Boran M; Doruk E; Gönenç F; Cetin S
Int Urol Nephrol; 1997; 29(2):251-8. PubMed ID: 9241557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
